Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002522 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by Temple University.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00002522: Completed Phase 2 study of Lymphoma, sponsored by Temple University.
NCT00002522 is a Phase 2 study of Lymphoma that has completed, run by Temple University. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002522, a Phase 2 study of Lymphoma, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients with relapsed or refractory Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- DRUG etoposide
- PROCEDURE bone marrow ablation with stem cell support
- PROCEDURE autologous bone marrow transplantation
Study Locations (1)
Pennsylvania
- Fox Chase - Temple Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Start Date | 1993-02 |
| Est. Completion | 2002-02 |
| Phase | Phase 2 |
What the finished NCT00002522 record still lists
NCT00002522 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00002522 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00002522 about?
NCT00002522 is a clinical study titled "Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE:...
What is the current status of trial NCT00002522?
This trial is currently completed. It is a Phase 2 study. The study started on 1993-02. Estimated completion is 2002-02.
What conditions does trial NCT00002522 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00002522?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), bone marrow ablation with stem cell support (PROCEDURE), autologous bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00002522?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002522 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia